Close
CDMO Safety Testing 2026
Novotech

Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.
- Advertisement -

Shire plc, the global specialty biopharmaceutical company, today announced the appointment of two senior Research & Development executives to its Specialty Pharmaceuticals business. Lawson Macartney, DVM, PhD, FRCPath, has been appointed Senior Vice President of the Emerging Business Unit and Mario Saltarelli, MD, PhD, has been named Senior Vice President of Clinical Development and Medical Affairs. The experience and expertise that Drs. Macartney and Saltarelli bring to the Shire team will help us advance our pipeline, more effectively manage the lifecycle of our medicines, and provide growth opportunities โ€“ all in the spirit of helping patients with life-altering conditions to lead better lives,โ€ said Jeffrey M. Jonas, MD, Senior Vice President of Research & Development for Shireโ€™s Specialty Pharmaceuticals business and to whom Drs. Macartney and Saltarelli will report.

As leader of Shireโ€™s Emerging Business Unit, Dr. Macartney is responsible for the early pipeline and development efforts of Shireโ€™s Specialty Pharmaceuticals business, which is centered on attention deficit hyperactivity disorder (ADHD) and gastrointestinal diseases.ย  Based initially in Shireโ€™s Wayne, PA office and transitioning to Shireโ€™s Nyon, Switzerland office, Dr. Macartney will direct the Research & Development evaluation of new product opportunities and explore new therapeutic areas for Shireโ€™s Specialty Pharmaceuticals business.

Dr. Macartney brings to Shire a wealth of global drug development and commercialization experience.ย  He spent nearly 20 years working with GlaxoSmithKline (GSK) where he most recently served as Senior Vice President of Global Product Strategy and Project/Portfolio Management. Throughout his time at GSK, Dr. Macartney held leadership roles in the Cardiopulmonary Therapeutic Area, from Project Leader to Global Head for Cardiovascular, Metabolic and Urology. Prior to his experience at GSK, he worked at AstraMerck and Astra Pharmaceuticals in leadership roles in operations, marketing and customer service. Dr. Macartney is trained as a veterinarian and received his Ph.D. from Glasgow University Veterinary School in Scotland where he was a Royal Society Research Fellow.

In his role as Senior Vice President of Clinical Development & Medical Affairs for Shireโ€™s Specialty Pharmaceuticals business, Dr. Saltarelli will be based in Shireโ€™s Wayne, PA offices and provide overall scientific and professional leadership as well as clinical and medical strategies for Shireโ€™s global drug development programs.

Dr. Saltarelliโ€™s diverse background spans nearly two decades across medical science, clinical drug development, and the scientific and regulatory aspects of clinical program design. He joins Shire from Abbott Laboratories where he served as the Divisional Vice President directly accountable for all aspects of clinical development, medical affairs, and development strategy for Global Neuroscience and Anesthesia products. Prior to that, Dr. Saltarelli spent seven years at Pfizer Global Research and Development in Connecticut, ultimately as Executive Director of the CNS Early Clinical Development Group, and he served for four years as an Assistant Professor of Neurology at Emory University School of Medicine. Dr. Saltarelli earned a BS in Psychology from the University of Illinois at Urbana-Champaign, an MD in Medicine and a PhD in Neuropharmacology from The Johns Hopkins University.ย  Dr. Saltarelli was an intern at the University of Maryland Medical Center and spent his Neurology residency at Johns Hopkins Hospital.

Latest stories

Related stories

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum Computing Optimizing Pharma Supply Chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป